Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EZETIMIBE vs BEMPEDOIC ACID AND EZETIMIBE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestine, reducing intestinal absorption of dietary and biliary cholesterol, leading to decreased hepatic cholesterol stores and increased clearance of cholesterol from the blood.
Bempedoic acid inhibits ATP-citrate lyase, reducing cholesterol synthesis; ezetimibe inhibits intestinal absorption of cholesterol via Niemann-Pick C1-like 1 protein.
Adjunctive therapy to diet for reduction of elevated total cholesterol, LDL-C, and apolipoprotein B in patients with primary hyperlipidemia (heterozygous familial and non-familial),Homozygous familial hypercholesterolemia (Ho FH) in combination with other lipid-lowering treatments,Homozygous sitosterolemia (phytosterolemia),Mixed hyperlipidemia (in combination with fenofibrate),Prevention of cardiovascular events in patients with coronary heart disease (in combination with simvastatin, off-label use),Reduction of residual cardiovascular risk in patients with a history of acute coronary syndrome (off-label use)
Adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease requiring additional LDL-C lowering.
10 mg orally once daily, with or without food, at any time of day.
Bempedoic acid 180 mg and ezetimibe 10 mg orally once daily.
Approximately 22 hours for ezetimibe and its active glucuronide metabolite; steady-state achieved within 3-7 days.
Bempedoic acid: terminal half-life approximately 21 hours (range 15–24 hours), consistent with once-daily dosing. Ezetimibe: terminal half-life approximately 22 hours for ezetimibe and its glucuronide conjugate, supporting once-daily dosing.
Primarily metabolized via glucuronidation by UGT1A1, UGT1A3, and UGT2B15; minimal CYP450 involvement (negligible oxidative metabolism). Ezetimibe and ezetimibe-glucuronide undergo enterohepatic recycling. Elimination is via biliary and fecal routes; renal excretion is minimal.
Bempedoic acid: primarily glucuronidation (UGT2B7), minor oxidation (CYP450); ezetimibe: glucuronidation (UGT1A1, UGT1A3) to active phenolic glucuronide.
Biliary and fecal: ~78% as parent compound; renal: ~11% as metabolite; enterohepatic recirculation occurs.
Bempedoic acid is primarily excreted via the biliary/fecal route (approximately 90%), with renal excretion accounting for <10% as unchanged drug. Ezetimibe is excreted primarily in feces (78%) via biliary elimination, with renal excretion <10% as unchanged drug.
>99.7% bound to human plasma proteins, primarily albumin.
Bempedoic acid: >99% bound to plasma proteins (primarily albumin). Ezetimibe: >90% bound to plasma proteins (albumin). The active glucuronide metabolite of ezetimibe is also highly protein bound (~90%).
Not applicable; ezetimibe has a Vd of approximately 18 L/kg due to extensive tissue distribution, but clinical relevance is limited.
Bempedoic acid: Vd approximately 18 L (0.25 L/kg for a 70 kg adult), indicating moderate tissue distribution. Ezetimibe: Vd approximately 10–20 L (0.14–0.29 L/kg), suggesting distribution into tissues.
Oral: variable; estimated ~35-65% due to extensive glucuronidation and enterohepatic recycling.
Bempedoic acid: oral bioavailability not well characterized due to extensive presystemic metabolism; absolute bioavailability estimated at 10–20% (based on AUC ratios). Ezetimibe: rapidly absorbed and extensively glucuronidated; absolute bioavailability estimated at 35–65% due to first-pass metabolism. Both are administered orally.
No dose adjustment required for any degree of renal impairment including end-stage renal disease.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m²). Not recommended in severe renal impairment (e GFR <30 m L/min/1.73 m²) or ESRD.
Contraindicated in patients with moderate (Child-Pugh B) to severe (Child-Pugh C) hepatic impairment. Use with caution in mild hepatic impairment without clear dose recommendations.
Contraindicated in moderate to severe hepatic impairment (Child-Pugh class B or C). No adjustment needed for mild impairment (Child-Pugh class A).
Children ≥10 years: 10 mg orally once daily. Children <10 years: safety and efficacy not established; use not recommended.
Safety and efficacy not established in pediatric patients.
No specific dose adjustment needed. Use standard adult dosing based on clinical studies including patients >65 years.
No specific dose adjustment required; monitor renal function and potential for drug interactions due to age-related changes.
None.
No black box warning.
Hepatic impairment: Not recommended in moderate to severe liver dysfunction; monitor liver enzymes when coadministered with statins or fenofibrate.,Myopathy/Rhabdomyolysis: Increased risk when used with statins, especially at higher doses; caution in patients with predisposing factors (e.g., renal impairment, hypothyroidism).,Pancreatitis: Rare cases reported, especially with concomitant fenofibrate.,Cholelithiasis: May increase cholesterol secretion into bile, potentially causing gallstones; use caution in patients with biliary obstruction.,Hypersensitivity: Monitor for allergic reactions (e.g., angioedema, rash, urticaria).,Fetal risk: Use only if clearly needed in pregnancy (Category C); discontinue nursing or drug in lactating women.,Pediatric use: Safety and efficacy established in adolescents (≥10 years) for Ho FH and sitosterolemia; not recommended for primary hyperlipidemia in pediatric patients <10 years.
Risk of myopathy and rhabdomyolysis (especially with statins),Hyperuricemia,Tendon rupture,Increased risk of nephrolithiasis,Elevated liver enzymes,Fetal toxicity (based on animal data)
Hypersensitivity to ezetimibe or any component of the formulation.,Active liver disease or unexplained persistent elevations in serum transaminases (when used with a statin).,Coadministration with a statin in pregnant or nursing women (relative contraindication).
Concurrent use with simvastatin >20 mg or pravastatin >40 mg,Severe hepatic impairment,Pregnancy and lactation
No significant food interactions. Avoid high-fat meals if combined with statins (to minimize statin-related myopathy risk). Bile acid sequestrants (e.g., cholestyramine) should be taken at least 4 hours before or 2 hours after ezetimibe to reduce absorption interference.
Grapefruit juice may increase bempedoic acid exposure; avoid concurrent consumption. No specific dietary restrictions for ezetimibe; however, a low-fat, low-cholesterol diet enhances efficacy.
Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. FDA Pregnancy Category C. No known risk of congenital anomalies based on limited data, but cannot exclude risk; avoid use in first trimester unless clearly needed.
Bempedoic acid: No human data; animal studies show no teratogenicity at exposures up to 6 times human AUC. Ezetimibe: No evidence of teratogenicity in animal studies; limited human data show no increased risk of major malformations. First trimester: No known risk, but caution advised due to lack of robust human data. Second/third trimester: No known fetal risks. Avoid use unless clearly needed.
Unknown if excreted in human breast milk; no data on M/P ratio. Due to potential for serious adverse reactions in nursing infants, decision should be made to discontinue nursing or drug, considering importance of drug to mother.
Bempedoic acid: No data on excretion in human milk; molecular weight suggests possible excretion. Ezetimibe: Excreted in rat milk; unknown in humans. M/P ratio not available. Due to unknown risks, breastfeeding not recommended during therapy. Consider alternative agents.
No pharmacokinetic data indicate need for dose adjustment during pregnancy; use same dose as non-pregnant adults if clinically indicated.
No pharmacokinetic data in pregnancy for either component. Pregnancy may alter drug metabolism; however, no dose adjustment guidelines exist. Use lowest effective dose if necessary. Avoid combination use; if indicated, each drug should be considered separately.
Ezetimibe inhibits intestinal absorption of cholesterol via the Niemann-Pick C1-like 1 (NPC1L1) protein. It is often used as adjunctive therapy to statins for LDL-C lowering. Unlike statins, it does not affect hepatic HMG-Co A reductase and has minimal drug interactions, making it useful for statin-intolerant patients. It can be combined with fenofibrate but caution with gemfibrozil due to increased risk of cholelithiasis. Contraindicated in active liver disease or unexplained persistent transaminase elevations. No dose adjustment needed in chronic kidney disease.
Bempedoic acid + ezetimibe is used as adjunct to diet and maximally tolerated statin for LDL-C reduction. Bempedoic acid is a prodrug activated in the liver; avoid in severe hepatic impairment. Ezetimibe inhibits intestinal cholesterol absorption. Monitor for myalgia, tendon rupture (bempedoic acid), and increased uric acid (gout risk). Check LFTs at baseline and periodically. Contraindicated with simvastatin >20 mg due to increased myopathy risk.
Take ezetimibe exactly as prescribed, usually once daily with or without food.,It is usually taken in addition to a statin or other cholesterol-lowering medications.,You may experience mild side effects such as diarrhea, joint pain, or upper respiratory infection.,Rarely, serious muscle pain or liver problems can occur; report unexplained muscle aches, tenderness, or weakness, especially if accompanied by fever or dark urine.,Keep taking the medication even if you feel well, as high cholesterol has no symptoms.,Do not stop or change your dose without discussing with your doctor.,Inform your healthcare provider about all other medications, especially bile acid sequestrants (e.g., cholestyramine) which may reduce ezetimibe absorption.,Pregnancy and breastfeeding: Use only if clearly needed; discuss with your doctor.
Take this medication exactly as prescribed, usually once daily with or without food.,Continue a heart-healthy diet and exercise; this drug is not a substitute for lifestyle changes.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or dark urine.,Tell your doctor if you have a history of gout, as this drug can raise uric acid levels.,Avoid grapefruit juice while taking this medication (bempedoic acid interacts).,Do not take with other cholesterol-lowering medicines containing simvastatin >20 mg.
"Nicergoline, an ergot derivative with alpha-adrenergic blocking and vasodilatory properties, may enhance the cholesterol-lowering effects of ezetimibe by increasing its bioavailability through inhibition of intestinal P-glycoprotein (P-gp) and OATP1B1 transporters. This interaction can lead to elevated plasma concentrations of ezetimibe, potentially increasing the risk of adverse effects such as myopathy, rhabdomyolysis, and hepatotoxicity. Clinicians should monitor for signs of muscle pain or liver enzyme abnormalities when these drugs are coadministered."
"Lovastatin, a HMG-CoA reductase inhibitor, can increase the systemic exposure of ezetimibe, a cholesterol absorption inhibitor, via inhibition of OATP1B1 and possibly other transporters, leading to elevated ezetimibe-glucuronide concentrations. This interaction potentiates the lipid-lowering effect but may also increase the risk of ezetimibe-related adverse effects, such as myalgia or transaminase elevations, although clinical significance is generally low. The combination is often used intentionally for additive LDL-C reduction in patients requiring intensive lipid management."
"Coadministration of lisuride, a dopamine receptor agonist, and ezetimibe, a cholesterol absorption inhibitor, may theoretically increase the risk of adverse effects such as hypotension, syncope, and gastrointestinal disturbances. Lisuride can cause orthostatic hypotension and dizziness, and concomitant use with ezetimibe, which has been associated with rare cases of myopathy and hepatic enzyme elevations, may additively impair hemodynamic stability or hepatic function. Clinical vigilance is warranted as the combined pharmacological profiles could potentiate central nervous system depressant effects or unforeseen drug-drug interactions, especially in elderly patients."
"Nicergoline, an ergot derivative with alpha-adrenergic blocking and vasodilatory properties, may enhance the cholesterol-lowering effects of ezetimibe by increasing its bioavailability through inhibition of intestinal P-glycoprotein (P-gp) and OATP1B1 transporters. This interaction can lead to elevated plasma concentrations of ezetimibe, potentially increasing the risk of adverse effects such as myopathy, rhabdomyolysis, and hepatotoxicity. Clinicians should monitor for signs of muscle pain or liver enzyme abnormalities when these drugs are coadministered."
"Lovastatin, a HMG-CoA reductase inhibitor, can increase the systemic exposure of ezetimibe, a cholesterol absorption inhibitor, via inhibition of OATP1B1 and possibly other transporters, leading to elevated ezetimibe-glucuronide concentrations. This interaction potentiates the lipid-lowering effect but may also increase the risk of ezetimibe-related adverse effects, such as myalgia or transaminase elevations, although clinical significance is generally low. The combination is often used intentionally for additive LDL-C reduction in patients requiring intensive lipid management."
"Coadministration of lisuride, a dopamine receptor agonist, and ezetimibe, a cholesterol absorption inhibitor, may theoretically increase the risk of adverse effects such as hypotension, syncope, and gastrointestinal disturbances. Lisuride can cause orthostatic hypotension and dizziness, and concomitant use with ezetimibe, which has been associated with rare cases of myopathy and hepatic enzyme elevations, may additively impair hemodynamic stability or hepatic function. Clinical vigilance is warranted as the combined pharmacological profiles could potentiate central nervous system depressant effects or unforeseen drug-drug interactions, especially in elderly patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EZETIMIBE vs BEMPEDOIC ACID AND EZETIMIBE, answered by our medical review team.
EZETIMIBE is a Cholesterol Absorption Inhibitor that works by Inhibits Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestine, reducing intestinal absorption of dietary and biliary cholesterol, leading to decreased hepatic cholesterol stores and increased clearance of cholesterol from the blood.. BEMPEDOIC ACID AND EZETIMIBE is a Cholesterol Absorption Inhibitor that works by Bempedoic acid inhibits ATP-citrate lyase, reducing cholesterol synthesis; ezetimibe inhibits intestinal absorption of cholesterol via Niemann-Pick C1-like 1 protein.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EZETIMIBE and BEMPEDOIC ACID AND EZETIMIBE depend on the specific clinical indication. These are both Cholesterol Absorption Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EZETIMIBE is: 10 mg orally once daily, with or without food, at any time of day.. The standard adult dose of BEMPEDOIC ACID AND EZETIMIBE is: Bempedoic acid 180 mg and ezetimibe 10 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EZETIMIBE and BEMPEDOIC ACID AND EZETIMIBE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EZETIMIBE is classified as Category A/B. Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. FDA Pregnancy Category C. No known risk of congenital anomalies based on li. BEMPEDOIC ACID AND EZETIMIBE is classified as Category A/B. Bempedoic acid: No human data; animal studies show no teratogenicity at exposures up to 6 times human AUC. Ezetimibe: No evidence of teratogenicity in animal studies; limited human. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.